AbbVie's SEZ6-Targeting ADC ABBV-706 Receives CDE Clinical Trial Acceptance in China

Sep 25, 2024 15:48 CST Updated 15:48

AbbVie

Innovative Drug Developer

On September 25, the CDE website announced that AbbVie's SEZ6-targeted ADC drugABBV-706 Clinical Application in China Accepted.

CDE Official Website

ABBV-706 is an ADC targeting SEZ6, conjugated with the toxin topoisomerase 1 inhibitor TOP1i through a Valine-alanine linker, with a DAR of 6. ABBV-706 can target tumor cells expressing SEZ6, rapidly internalize, and deliver the Top1i payload to kill tumor cells.

Introduction to ABBV-706 on the Official Website

At the 2024 ASCO Annual Meeting,AbbVie announced in the form of an oral reportABBV-706Early data from the single-agent dose-escalation portion of the first-in-human study.

Abstract of ABBV-706 Presented at ASCO

At the 2024 ASCO Annual Meeting, AbbVie Inc. presented preliminary clinical study data on ABBV-706 in patients with advanced solid tumors. The data included statistical results as of November 15, 2023, and updated data as of March 20, 2024.

As of November 15, 2023, among 33 evaluable patients, the objective response rate (ORR) was 21%, with seven patients achieving partial responses. Notably, the ORR in small cell lung cancer (SCLC) patients reached 40%, while the ORR in neuroendocrine neoplasm (NEN) patients was 6%. The main adverse events included anemia (51%), fatigue (41%), neutropenia (31%), and leukopenia (31%), with no cases of pneumonia or interstitial lung disease observed. A dose of 3 mg/kg administered intravenously every three weeks was considered the maximum tolerated dose. Additionally, the unconfirmed overall response rate was 45%, with 73% in SCLC patients and 22% in NEN patients, and the clinical benefit rate reached 91%.

As of March 20, 2024, the confirmed ORR among 48 evaluable patients increased to 44%, with an ORR of 60.9% in SCLC patients and 28% in NEN patients. The main adverse events were neutropenia (42%), anemia (42%), and leukopenia (28%).

Phase 1 Clinical Trial of ABBV-706 (NCT05599984)

CurrentlyABBV-706 is currently in Phase 1 clinical trials.Evaluate ABBV-706 as a single agent or in combination with Budigalimab (ABBV-181), carboplatin, or cisplatin for the treatment of patients with advanced solid tumors, including SCLC and other NEN.

To promote the exchange and innovation in the antibody industry,October 16-17, 2024The 7th Golden Autumn October Antibody Industry Development ConferenceAs scheduled. The conference aims to provide researchers with an interactive communication platform, which will help promote the further development of the antibody industry.

Meeting Content

Time:October 16-17, 2024

Location: Zhangjiang, Shanghai(Hotel Directional Notice)

Scale:600-800 people

Hosted by:Biopharmaceutical Circle, Antibody Circle

Speech Support:Entegris, Reservoir Diagnostics, AS ONE CORPORATION

Conference Fee:Free FREE!(Only charge100YuanRegistration deposit (includes participation in learning sessions, tea breaks, and conference materials; the deposit is non-refundable). First come, first served, until fully booked.！

Registration Method:Scan the QR code below or click "Read Original" at the bottom of the article → Fill out the form → Registration successful (Volunteer registration,Undertake certain work, please consider carefully, no deposit required.）！

After the organizing committee receives the registration information, they will conduct an initial screening based on the information and further communicate with registrants for confirmation to extend precise invitations. Those who pass the strict review will ultimately have the opportunity to join the conference WeChat group.

Schedule

More guests are being invited.

Scan the WeChat QR code to add the editor of Antibody Circle.Those who meet the requirements can join the Antibody Circle WeChat group!

Please indicate: Name + Research Direction!

All articles reproduced in this official account are intended to convey more information, with the source and author clearly indicated. Media or individuals who do not wish to be reprinted may contact us (cbplib@163.com), and we will immediately delete the content. All articles represent the views of the author and do not represent the position of this website.